← FDA DRUG APPROVALS

FDA ANDA · ANDA072073

NALBUPHINE HYDROCHLORIDE

Sponsor: IGI LABS INC

APPLICATION
ANDA072073
TYPE
ANDA
ROUTE
INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Discontinued

Products

NALBUPHINE HYDROCHLORIDEDiscontinued
NALBUPHINE HYDROCHLORIDE 20MG/ML (20MG/ML) · SOLUTION · INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
NALBUPHINE HYDROCHLORIDEDiscontinued
NALBUPHINE HYDROCHLORIDE 200MG/10ML (20MG/ML) · SOLUTION · INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →